MedKoo Biosciences/ABT751/200050/20g

Synonym:ABT751;ABT-751;ABT751;E7010;E-7010;E7010

IUPAC/ChemicalName:N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide

InChiKey:URCVCIZFVQDVPM-UHFFFAOYSA-N

InChiCode:InChI=1S/C18H17N3O4S/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13/h2-12,21-22H,1H3,(H,19,20)

SMILESCode:O=S(C1=CC=C(OC)C=C1)(NC2=CC=CN=C2NC3=CC=C(O)C=C3)=O

TechnicalData

AdditionalInformation

RelatedCAS#
141430-65-1(ABT-751)
857447-92-8(previousassignedforABT-751'sCAS#,itwasdeletednow)

References

1:FoxE,Mosse'YP,MeanyHM,GurneyJG,KhannaG,JacksonHA,GordonG,ShustermanS,ParkJR,CohnSL,AdamsonPC,LondonWB,MarisJM,BalisFM.TimetodiseaseprogressioninchildrenwithrelapsedorrefractoryneuroblastomatreatedwithABT-751:areportfromtheChildren'sOncologyGroup(ANBL0621).PediatrBloodCancer.2014Jun;61(6):990-6.doi:10.1002/pbc.24900.Epub2013Dec18.PubMedPMID:24347462.

2:InnocentiF,RamírezJ,ObelJ,XiongJ,MirkovS,ChiuYL,KatzDA,CarrRA,ZhangW,DasS,AdjeiA,MoyerAM,ChenPX,KrivoshikA,MedinaD,GordonGB,RatainMJ,SahelijoL,WeinshilboumRM,FlemingGF,BhathenaA.PreclinicaldiscoveryofcandidategenestoguidepharmacogeneticsduringphaseIdevelopment:theexampleofthenovelanticanceragentABT-751.PharmacogenetGenomics.2013Jul;23(7):374-81.doi:10.1097/FPC.0b013e3283623e81.PubMedPMID:23670235;PubMedCentralPMCID:PMC3858967.

3:MaT,FuldAD,RigasJR,HageyAE,GordonGB,DmitrovskyE,DragnevKH.AphaseItrialandinvitrostudiescombiningABT-751withcarboplatininpreviouslytreatednon-smallcelllungcancerpatients.Chemotherapy.2012;58(4):321-9.doi:10.1159/000343165.Epub2012Nov12.PubMedPMID:23147218;PubMedCentralPMCID:PMC3570826.

4:GaynonPS,HarnedTM;TherapeuticAdvancesinChildhoodLeukemia/LymphomaConsortium.ABT-751inrelapsedchildhoodacutelymphoblasticleukemia.JPediatrHematolOncol.2012Oct;34(7):583-4.PubMedPMID:22584778.

5:SilverM,RuskA,PhillipsB,BeckE,JankowskiM,PhilibertJ,HahnK,HersheyE,McKeeganE,BauchJ,KrivoshikA,KhannaC.Evaluationoftheoralantimitoticagent(ABT-751)indogswithlymphoma.JVetInternMed.2012Mar-Apr;26(2):349-54.doi:10.1111/j.1939-1676.2012.00892.x.Epub2012Feb28.PubMedPMID:22369215.

6:RudinCM,MauerA,SmakalM,JuergensR,SpeldaS,WertheimM,CoatesA,McKeeganE,AnsellP,ZhouX,QianJ,PradhanR,DowellB,KrivoshikA,GordonG.PhaseI/IIstudyofpemetrexedwithorwithoutABT-751inadvancedormetastaticnon-small-celllungcancer.JClinOncol.2011Mar10;29(8):1075-82.doi:10.1200/JCO.2010.32.5944.Epub2011Feb7.PubMedPMID:21300929.

7:FoxE,MarisJM,CohnSL,GoodspeedW,GoodwinA,KromplewskiM,MedinaD,XiongH,KrivoshikA,WidemannB,AdamsonPC,BalisFM.PharmacokineticsoforallyadministeredABT-751inchildrenwithneuroblastomaandothersolidtumors.CancerChemotherPharmacol.2010Sep;66(4):737-43.doi:10.1007/s00280-009-1218-z.Epub2010Jan1.PubMedPMID:20044751.

8:MeanyHJ,SackettDL,MarisJM,WardY,KrivoshikA,CohnSL,SteinbergSM,BalisFM,FoxE.ClinicaloutcomeinchildrenwithrecurrentneuroblastomatreatedwithABT-751andeffectofABT-751onproliferationofneuroblastomacelllinesandontubulinpolymerizationinvitro.PediatrBloodCancer.2010Jan;54(1):47-54.doi:10.1002/pbc.22267.PubMedPMID:19731320;PubMedCentralPMCID:PMC2783914.

9:MichelsJ,EllardSL,LeL,KollmannsbergerC,MurrayN,TomlinsonGunsES,CarrR,ChiKN.AphaseIBstudyofABT-751incombinationwithdocetaxelinpatientswithadvancedcastration-resistantprostatecancer.AnnOncol.2010Feb;21(2):305-11.doi:10.1093/annonc/mdp311.Epub2009Jul24.PubMedPMID:19633045.

10:LuoY,HradilVP,FrostDJ,RosenbergSH,GordonGB,MorganSJ,GagneGD,CoxBF,TahirSK,FoxGB.ABT-751,anoveltubulin-bindingagent,decreasestumorperfusionanddisruptstumorvasculature.AnticancerDrugs.2009Jul;20(6):483-92.doi:10.1097/CAD.0b013e32832c0acf.PubMedPMID:19398903.